Prostate Cancer Clinical Trials in Nashville

Showing 261-280 of 306 trials

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

NCT01497431

This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or selenomethionine, two different types of selenium compounds, may prevent prostate cancer from forming.

No Evidence of DiseaseProstate Carcinoma

National Cancer Institute (NCI)66 participantsStarted Nov 2011

Chicago, Illinois, United States • Buffalo, New York, United States • Nashville, Tennessee, United States

COMPLETEDPhase 1< 1 mile

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

NCT00314782

Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)

Prostate Cancer

AstraZeneca44 participantsStarted Mar 2006

Buffalo, New York, United States • Greenville, South Carolina, United States • Nashville, Tennessee, United States +6 more locations

COMPLETEDPhase 4157 miles

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

NCT01161563

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

Prostate Cancer

Watson Pharmaceuticals118 participantsStarted Jul 2010

Homewood, Alabama, United States • Daytona Beach, Florida, United States • Orange City, Florida, United States +13 more locations

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Prostate Cancer Trials in Other Cities

A Trial of Degarelix in Patients With Prostate Cancer

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

3-AP in Treating Patients With Advanced Prostate Cancer

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Other Conditions in Nashville